Skin adverse events of PD-1 inhibitors may be marker of prognosis

Cutaneous immune‐related adverse effects (irAEs) are becoming more apparent with the increasing use of immune checkpoint inhibitors (ICIs) in melanoma patients, dermatologists say. According to a Commentary in the British Journal of Dermatology, the PD‐1 inhibitors are now a first-line option in metastatic melanomas and also show significant potential in the treatment of advanced‐stage squamous and ...